Oruka Therapeutics, Inc. (ORKA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.15B
Last updated: Nov 17, 2026 at 11:06 AM ET
Oruka Therapeutics, Inc. (ORKA) Stock Forecast
Analysts expect Oruka Therapeutics (ORKA) to earn -$2.45 per share in the fiscal year ending Dec 31, 2026. Of 13 analysts, 13 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 8 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 1.85, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 15.4% |
| Buy | 11 | 84.6% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$2.45
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$2.95
- EPS consensus
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$2.45 | -$2.66 to -$2.07 | 7 |
| Dec 31, 2027 | -$2.95 | -$4.09 to -$2.14 | 9 |
Quarterly Estimates
The EPS consensus falls from -$0.69 for the quarter ending Dec 31, 2026 to -$0.73 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.69 | -$0.98 to -$0.38 | 14 |
| Mar 31, 2027 | -$0.73 | -$0.88 to -$0.60 | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 18 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 8 |
| Fiscal year ending Dec 31, 2027 | 3 | 6 |
| Quarter ending Mar 31, 2027 | 1 | 4 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$2.28.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.45 | -$2.37 | -$2.37 | -$2.37 | -$2.28 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.95 | -$2.86 | -$2.86 | -$2.86 | -$2.77 | N/A |
| Quarter ending Mar 31, 2027 | -$0.73 | -$0.72 | -$0.72 | -$0.72 | -$0.68 | N/A |
Frequently Asked Questions About ORKA
What is the ORKA stock forecast?
Consensus analyst estimates put Oruka Therapeutics's EPS at -$2.45 for the fiscal year ending Dec 31, 2026. The consensus rating from 13 analysts is Buy.
How do analysts rate ORKA stock?
Of 13 analysts covering Oruka Therapeutics, 2 rate it Strong Buy, 11 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ORKA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.45, with estimates from -$2.66 to -$2.07 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.95, with estimates from -$4.09 to -$2.14 from 9 analysts.
How many analysts cover ORKA?
13 analysts rate Oruka Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.